Japanese encephalitis: Pathogenesis, prophylactics and therapeutics

Current Science

Volumn 98, Issue 3, 2010, Pages 326-334

  Dutta, Kallol ^a   Rangarajan, Pundi N ^b   Vrati, Sudhanshu ^c   Basu, Anirban ^a  

^a NATIONAL BRAIN RESEARCH CENTRE   (India)

^b INDIAN INSTITUTE OF SCIENCE   (India)

^c NATIONAL INSTITUTE OF IMMUNOLOGY   (India)

Author keywords

Central neurons system; Flavivirus; Japanese encephalitis virus; Prophylaxis; Vaccine

Indexed keywords

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS;

EID: 77953346430     PISSN: 00113891     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. Solomon, T., Dung, N. M., Kneen, R., Gainsborough, M., Vaughn, D. W. and Khanh, V. T., Japanese encephalitis. J. Neurol. Neurosurg. Psychiatry., 2000, 68, 405-415.
2. Gould, E. A., Evolution of the Japanese serological group viruses. In Current Topics in Microbiology and Immunology: Japanese Encephalitis and West Nile Virus Infections (eds Mackenzie, J. S., Barrett, A. D. and Deubel, V.), Springer-Verlag, Berlin, 2002, pp. 391-404.
3. Solomon, T., Ni, H., Beasley, D. W., Ekkelenkamp, M., Cardosa, M. J. and Barrett, A. D. T., Origin and evolution of Japanese encephalitis virus in southeast Asia. J. Virol., 2003, 77, 3091-3098.
4. Solomon, T., Control of Japanese encephalitis - within our grasp? N. Engl. J. Med., 2006, 355, 869-871.
5. Tsai, T. F., New initiatives for the control of Japanese encephalitis by vaccination: minutes of a WHO/CVI meeting, Bangkok, Thailand, 13-15 October 1998. Vaccine, 2000, 18, 1-25.
6. Dhillon, G. P. and Raina, V. K., Epidemiology of Japanese encephalitis in context with Indian scenario. J. Indian. Med. Assoc., 2008, 106, 660-663.
7. Kabilan, L., Rajendran, R., Arunachalam, N., Rameshm, S., Srinivasan, S., Samuel, P. P. and Dash, A. P., Japanese encephalitis in India: an overview. Indian J. Pediatr., 2004, 71, 609-615.
8. Takahashi, M. and Suzuki, K., Japanese encephalitis virus in mosquito salivary glands. Am. J. Trop. Med. Hyg., 1979, 28, 122-135.
9. Zeidner, N. S., Higgs, S., Happ, C. M., Beaty, B. J. and Miller, B. R., Mosquito feeding modulates Th1 and Th2 cytokines in flavivirus susceptible mice: an effect mimicked by injection of sialokinins, but not demonstrated in flavivirus resistant mice. Parasite Immunol., 1999, 21, 35-44.
10. Innis, B. L., Japanese encephalitis. In Exotic Viral Infections (ed. Porterfield, J. S.), Chapman and Hall, London, 1995, pp. 147-174.
11. Solomon, T., Recent advances in Japanese encephalitis. J. Neurovirol., 2003, 9, 274-283.
12. Ghosh, D. and Basu, A., Japanese encephalitis - a pathological and clinical perspective. PLoS Negl. Trop. Dis. (in press).
13. Kaur, R. and Vrati, S., Development of a recombinant vaccine against Japanese encephalitis. J. Neurovirol., 2003, 9, 421-431.
14. Kim, J.-M., Yun, S.-I., Song, B.-H., Hahn, Y.-S., Lee, C.-H., Oh, H.-W. and Lee, Y.-M., A single N-linked glycosylation site in the Japanese encephalitis virus prM protein is critical for cell typespecific prM protein biogenesis, virus particle release, and pathogenicity in mice. J. Virol., 2008, 82, 7846-7862.
15. Ho, L.-J., Wang, J.-J., Shaio, M.-F., Kao, C.-L., Chang, D.-M., Han, S.-W. and Lai, J.-H., Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production. J. Immunol., 2001, 166, 1499-1506.
16. Johnston, L. J., Halliday, G. M. and King, N. J., Langerhans cells migrate to local lymph nodes following cutaneous infection with an arbovirus. J. Invest. Dermatol., 2000, 114, 560-568.
17. Solomon, T. and Vaughn, D. W., Pathogenesis and clinical features of Japanese encephalitis and West Nile virus infections. Curr. Top. Microbiol. Immunol., 2002, 267, 171-194.
18. Diamond, M. S., Evasion of innate and adaptive immunity by flaviviruses. Immunol. Cell Biol., 2003, 81, 196-206.
19. Yang, K. D. et al., A model to study neurotropism and persistency of Japanese encephalitis virus infection in human neuroblastoma cells and leukocytes. J. Gen. Virol., 2004, 85, 635-642.
20. Aleyas, A. G. et al., Functional modulation of dendritic cells and macrophages by japanese encephalitis virus through MyD88 adaptor molecule-dependent and -independent pathways. J. Immunol., 2009, 183, 2462-2474.
21. Mathur, A., Khanna, N. and Chaturvedi, U. C., Breakdown of blood-brain barrier by virus-induced cytokine during Japanese encephalitis virus infection. Int. J. Exp. Pathol., 1992, 73, 603-611.
22. Mishra, M. K., Dutta, K., Saheb, S. K. and Basu, A., Understanding the molecular mechanism of blood-brain barrier damage in an experimental model of Japanese encephalitis: correlation with minocycline administration as a therapeutic agent. Neurochem. Int., 2009 (in press).
23. Ghoshal, A. et al., Proinflammatory mediators released by activated microglia induces neuronal death in Japanese encephalitis. Glia, 2007, 55, 483-496
24. Swarup, V., Ghosh, J., Das, S. and Basu, A., Tumor necrosis factor receptor-associated death domain mediated neuronal death contributes to the glial activation and subsequent neuroinflammation in Japanese encephalitis. Neurochem. Int., 2008, 52, 1310-1321.
25. Lin, Y. L. et al., Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J. Virol., 1997, 71, 5227-5235.
26. Chen, C. J., Liao, S. L., Kuo, M. D. and Wang, Y. M., Astrocytic alteration induced by Japanese encephalitis virus infection. Neuroreport, 2000, 11, 1933-1937.
27. Kuhlow, C. J., Krady, J. K., Basu, A. and Levison, S. W., Astrocytic ceruloplasmin expression, which is induced by IL-1beta and by traumatic brain injury, increases in the absence of the IL-1 type 1 receptor. Glia, 2003, 44, 76-84.
28. Bhowmick, S., Duseja, R., Das, S., Appaiahgiri, M. B., Vrati, S. and Basu, A., Induction of IP-10 (CXCL10) in astrocytes following Japanese encephalitis. Neurosci. Lett., 2007, 414, 45-50.
29. Mishra, M. K., Koli, P., Bhowmick, S. and Basu, A., Neuroprotection conferred by astrocytes is insufficient to protect animals from succumbing to Japanese encephalitis. Neurochem. Int., 2007, 50, 764-73.
30. Saha, S. and Rangarajan, P, N., Common host genes are activated in mouse brain by Japanese encephalitis and rabies viruses. J. Gen. Virol., 2003, 84, 1729-1735.
31. Saha, S., Sugumar, P., Bhandari, P. and Rangarajan, P. N., Identification of Japanese encephalitis virus inducible genes in mouse brain and characterization of GARG39/IFIT2 as a microtubuleassociated protein. J. Gen. Virol., 2006, 87, 3285-3289.
32. Burke, D. S., Lorsomrudee, W., Leake, C. J., Hoke, C. H., Nisalak, A., Chongswasdi, V. and Laorakpongse, T., Fatal outcome in Japanese encephalitis. Am. J. Trop. Med. Hyg., 1985, 34, 203-1210.
33. Vaughn, D. W. and Hoke, C. H., The epidemiology of Japanese encephalitis: prospects for prevention. Epidemiol. Rev., 1992, 14, 197-221.
34. Solomon, T. et al., Poliomyelitis-like illness due to Japanese encephalitis virus. Lancet, 1998, 351, 1094-1097.
35. Kumar, S., Misra, U. K., Kalita, J., Sawani, V., Gupta, R. K. and Gujral, R., MRI in Japanese encephalitis. Am. J. Med. Sci., 1997, 39, 180-184.
36. Murgod, U. A., Muthane, U. B., Ravi, V., Radhesh, S. and Desai, A., Persistent movement disorders following Japanese encephalitis. Neurology, 2001, 57, 2313-2315.
37. Liao, C. H. et al., Involvement of nigrostriatal pathway in Japanese encephalitis with movement disorders: evidence from (99m)Tc-TRODAT-1 and (123)I-IBZM SPECT imagings. Mol. Imaging Biol., 2009 (in press).
38. Kalita, J. and Misra, U. K., EEG in Japanese encephalitis: a clinico-radiological correlation. Electroencephalogr. Clin. Neurophysiol., 1998, 106, 238-243.
39. Kumar, R., Mathur, A., Kumar, A., Sharma, S., Chakraborty, S. and Chaturvedi, U. C., Clinical features and prognostic indicators of Japanese encephalitis in children in Lucknow (India). Indian J. Med. Res., 1990, 91, 321-327.
40. Ishii, T., Matsushita, M. and Hamada, S., Characteristic residual neuropathological features of Japanese B encephalitis. Acta. Neuropathol., 1977, 38, 181-186.
41. Das, S. and Basu, A., Japanese encephalitis virus infects neural progenitor cells and decreases their proliferation. J. Neurochem., 2008, 106, 1624-1636.
42. Sasaki, O., Karoji, Y., Kuroda, A., Karaki, T., Takenokuma, K. and Maeda, O., Protection of pigs against mosquito-borne Japanese encephalitis virus by immunization with a live attenuated vaccine. Antiviral. Res., 1982, 2, 355-360.
43. Solomon, T., New vaccines for Japanese encephalitis. Lancet Neurol., 2008, 7, 116-118.
44. Shlim, D. R. and Solomon, T., Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin. Infect. Dis., 2002, 35, 183-188.
45. Okamoto, S. et al., Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus. Vaccine, 2008, 26, 589-594.
46. Gowal, D. and Tahlan, A. K., Evaluation of effectiveness of mouse brain inactivated Japanese encephalitis vaccine produced in India. Indian J. Med. Res., 1995, 102, 267-271.
47. http://www.expressindia.com/latest-news/Kasauli-CRIs-drug-licencesuspended/266285/
48. Jia, L., Wang, Z. and Yu, Y., Protection of SA14-14-2 live attenuated Japanese encephalitis vaccine against the wild-type JE viruses. Chin. Med. J. (Engl.), 2003, 116, 941-943.
49. Hennessy, S. et al., Effectiveness of live-attenuated Japanese encephalitis vaccine (SA14-14-2): a case-control study. Lancet, 1996, 347, 1583-1586.
50. http://www.who.int/vaccine_safety/topics/japanese_encephalitis/live_attenuated/June_2005/en/index.html
51. Tauber, E. et al., Safety and immunogenicity of a Verocell-derived, inactivated Japanese encephalitis vaccine: a noninferiority, phase III, randomised controlled trial. Lancet, 2007, 370, 1847-1853.
52. Appaiahgari, M. B. and Vrati, S., Immunogenicity and protective efficacy in mice of a formaldehyde-inactivated Indian strain of Japanese encephalitis virus grown in Vero cells. Vaccine, 2004, 22, 3669-3675.
53. Tartaglia, J. et al., NYVAC: a highly attenuated strain of vaccinia virus. Virology, 1992, 188, 217-232.
54. Konishi, E., Pincus, S., Paoletti, E., Laegreid, W. W., Shope, R. E. and Mason, P. W., A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology, 1992, 190, 454-458.
55. Nam, J. H., Wyatt, L. S., Chae, S. L., Cho, H. W., Park, Y. K. and Moss, B., Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes. Vaccine, 1999, 17, 261-268.
56. Konishi, E., Pincus, S., Paoletti, E., Shope, R. E. and Wason, P. W., Avipox virus-vectored Japanese encephalitis virus vaccines: use as vaccine candidates in combination with purified subunit immunogens. Vaccine, 1994, 12, 633-638.
57. Kanesa-thasan, N. et al., Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine, 2001, 19, 3179-3188.
58. Saini, M. and Vrati, S., A Japanese encephalitis virus peptide present on Johnson grass mosaic virus-like particles induces virusneutralizing antibodies and protects mice against lethal challenge. J. Virol., 2003, 77, 3487-3494.
59. Monath, T. P. et al., Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine, 1999, 17, 1869-1882.
60. Monath, T. P. et al., Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J. Virol., 2000, 74, 1742-1751.
61. Monath, T. P. et al., Clinical proof of principle for ChimeriVax: recombinant live, attenuated vaccines against flavivirus infections. Vaccine, 2002, 20, 1004-1018.
62. Bharati, K., Rani, R. and Vrati, S., Evaluation of Japanese encephalitis virus DNA vaccine candidates in rhesus monkeys [Macaca mulatta]. Vaccine, 2009, 27, 10-16.
63. Chang, G. J., Hunt, A. R. and Davis, B., A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J. Virol., 2000, 74, 4244-4252.
64. Kaur, R., Sachdeva, G. and Vrati, S., Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membraneanchored and secretory envelope protein. J. Infect. Dis., 2002, 185, 1-12.
65. Ashok, M. S. and Rangarajan, P. N., Protective efficacy of a plasmid DNA encoding Japanese encephalitis virus envelope protein fused to tissue plasminogen activator signal sequences: studies in a murine intracerebral virus challenge model. Vaccine, 2002, 20, 1563-1570.
66. Appaiahgari, M. B. and Vrati, S., DNAzyme-mediated inhibition of Japanese encephalitis virus replication in mouse brain. Mol. Ther., 2007, 15, 1593-1599.
67. Ramanathan, M. P. et al., Coimmunization with an optimized IL15 plasmid adjuvant enhances humoral immunity via stimulating B cells induced by genetically engineered DNA vaccines expressing consensus JEV and WNV E DIII. Vaccine, 2009, 27, 4370-4380.
68. Imoto, J. and Konishi, E., Needle-free jet injection of a mixture of Japanese encephalitis DNA and protein vaccines: a strategy to effectively enhance immunogenicity of the DNA vaccine in a murine model. Viral Immunol., 2005, 18, 205-212.
69. Ishikawa, T., Widman, D. G., Bourne, N., Konishi, E. and Mason, P. W., Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine, 2008, 26, 2772-2781.
70. Solomon, T. et al., Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet, 2003, 361, 821-826.
71. Zhao, C., Denison, C., Huibregtse, J. M., Gygi, S. and Krug, R. M., Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl. Acad. Sci. USA, 2005, 102, 10200-10205.
72. Yuan, W. and Krug, R. M., Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J., 2001, 20, 362-371.
73. Loo, Y. M. et al., Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc. Natl. Acad. Sci. USA, 2006, 103, 6001-6006.
74. Okumura, A., Lu, G., Pitha-Rowe, I. and Pitha, P. M., Innate antiviral response targets HIV-1 release by the induction of ubiquitinlike protein ISG15. Proc. Natl. Acad. Sci. USA, 2006, 103, 1440-1445.
75. Kumar, R., Tripathi, P., Baranwal, M., Singh, S., Tripathi, S. and Banerjee, G., Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin. Infect. Dis., 2009, 48, 400-406.
76. Swarup, V., Ghosh, J., Ghosh, S., Saxena, A. and Basu, A., Antiviral and anti-inflammatory effects of rosmarinic acid in an experimental murine model of Japanese encephalitis. Antimicrob. Agents Chemother., 2007, 51, 3367-3370.
77. Swarup, V., Ghosh, J., Mishra, M. K. and Basu, A., Novel strategy for treatment of Japanese encephalitis using arctigenin, a plant lignan. J. Antimicrob. Chemother., 2008, 61, 679-688.
78. Dutta, K., Ghosh, D. and Basu, A., Curcumin protects neuronal cells from Japanese encephalitis virus-mediated cell death and also inhibits infective viral particle formation by dysregulation of ubiquitin-proteasome system. J. Neuroimmune. Pharmacol., 2009, 4, 328-337.
79. Michaelis, M., Kleinschmidt, M. C., Doerr, H. W. and Cinatl Jr, J., Minocycline inhibits West Nile virus replication and apoptosis in human neuronal cells. J. Antimicrob. Chemother., 2007, 60, 981-986.
80. Mishra, M. K. and Basu, A., Minocycline neuroprotects, reduces microglial activation, inhibits caspase 3 induction, and viral replication following Japanese encephalitis. J. Neurochem., 2008, 105, 1582-1595.
81. Mishra, M. K., Ghosh, D., Duseja, R. and Basu, A., Antioxidant potential of Minocycline in Japanese encephalitis virus infection in murine neuroblastoma cells: correlation with membrane fluidity and cell death. Neurochem. Int., 2009, 54, 464-470.
82. Sebastian, L., Desai, A., Shampur, M. N., Perumal, Y., Sriram, D., Vasanthapuram, R., N-methylisatin-beta-thiosemicarbazone derivative (SCH 16) is an inhibitor of Japanese encephalitis virus infection in vitro and in vivo. J. Virol., 2008, 5, 64-75.
83. Wu, S. F., Lee, C. J., Liao, C. L., Dwek, R. A., Zitzmann, N. and Lin, Y. L., Antiviral effects of an iminosugar derivative on flavivirus infections. J. Virol., 2002, 76, 3596-3604.
84. Kumar, P., Lee, S. K., Shankar, P. and Manjunath, N., A single siRNA suppresses fatal encephalitis induced by two different flaviviruses. PLoS Med., 2006, 3, e96.